Genome-wide massively parallel sequencing of formaldehyde fixed-paraffin embedded (FFPE) tumor tissues for copy-number- and mutation-analysis.
BACKGROUND
Cancer re-sequencing programs rely on DNA isolated from fresh snap frozen tissues, the preparation of which is combined with additional preservation efforts. Tissue samples at pathology departments are routinely stored as formalin-fixed and paraffin-embedded (FFPE) samples and their use would open up access to a variety of clinical trials. However, FFPE preparation is incompatible with many down-stream molecular biology techniques such as PCR based amplification methods and gene expression studies.


RESULTS
Here we investigated the sample quality requirements of FFPE tissues for massively parallel short-read sequencing approaches. We evaluated key variables of pre-fixation, fixation related and post-fixation processes that occur in routine medical service (e.g. degree of autolysis, duration of fixation and of storage). We also investigated the influence of tissue storage time on sequencing quality by using material that was up to 18 years old. Finally, we analyzed normal and tumor breast tissues using the Sequencing by Synthesis technique (Illumina Genome Analyzer, Solexa) to simultaneously localize genome-wide copy number alterations and to detect genomic variations such as substitutions and point-deletions and/or insertions in FFPE tissue samples.


CONCLUSIONS
The application of second generation sequencing techniques on small amounts of FFPE material opens up the possibility to analyze tissue samples which have been collected during routine clinical work as well as in the context of clinical trials. This is in particular important since FFPE samples are amply available from surgical tumor resections and histopathological diagnosis, and comprise tissue from precursor lesions, primary tumors, lymphogenic and/or hematogenic metastases. Large-scale studies using this tissue material will result in a better prediction of the prognosis of cancer patients and the early identification of patients which will respond to therapy.
Schweiger
Michal R
MR
Department of Vertebrate Genomics, Max Planck Institute for Molecular Genetics, Berlin, Germany.
Kerick
Martin
M
Timmermann
Bernd
B
Albrecht
Marcus W
MW
Borodina
Tatjana
T
Parkhomchuk
Dmitri
D
Zatloukal
Kurt
K
Lehrach
Hans
H
D000293:Adolescent; D019295:Computational Biology; D004252:DNA Mutational Analysis / Q000379:methods; D005557:Formaldehyde / Q000737:chemistry*; D006801:Humans; D066298:In Vitro Techniques; D009369:Neoplasms / Q000378:metabolism*; D016612:Paraffin Embedding / Q000379:methods*; D017422:Sequence Analysis, DNA / Q000379:methods*; D016707:Tissue Fixation / Q000379:methods*
D005557:Formaldehyde